---
title: "Ibrance (palbociclib), all indications: Drug interactions questions"
description: "Drug interactions questions on Ibrance (palbociclib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Ibrance have? What Ibrance dose is used with a strong CYP3A inhibitor? Can you eat grapefruit while taking Ibrance? Can Ibrance tablets or capsules be taken with PPIs or antacids? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ibrance/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ibrance (palbociclib), all indications: Drug interactions questions

Manufacturer: Pfizer Laboratories Div Pfizer Inc  
Prescribing information: [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921), [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191)  
Indication pages: [HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)

## Drug interactions

<a id="ibrance-drug-interactions"></a>

### What drug interactions does Ibrance have?

> “Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme SULT2A1. In vivo, palbociclib is a time-dependent inhibitor of CYP3A.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Palbociclib%20is%20primarily%20metabolized%20by,a%20time%2Ddependent%20inhibitor%20of%20CYP3A.)

> “Coadministration of a strong CYP3A inhibitor (itraconazole) increased the plasma exposure of palbociclib in healthy subjects by 87%. Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole). Avoid grapefruit or grapefruit juice during IBRANCE treatment. If coadministration of IBRANCE with a strong CYP3A inhibitor cannot be avoided, reduce the dose of IBRANCE [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Coadministration%20of%20a%20strong%20CYP3A,%282.2%29%20and%20Clinical%20Pharmacology%20%2812.3%29%5D.)

> “Coadministration of a strong CYP3A inducer (rifampin) decreased the plasma exposure of palbociclib in healthy subjects by 85%. Avoid concomitant use of strong CYP3A inducers (e.g., phenytoin, rifampin, carbamazepine, enzalutamide, and St John's Wort) [see Clinical Pharmacology (12.3)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Coadministration%20of%20a%20strong%20CYP3A%20inducer,Wort%29%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

> “Coadministration of midazolam with multiple doses of IBRANCE increased the midazolam plasma exposure by 61%, in healthy subjects, compared to administration of midazolam alone. The dose of the sensitive CYP3A substrate with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) may need to be reduced, as IBRANCE may increase its exposure [see Clinical Pharmacology (12.3)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Coadministration%20of%20midazolam%20with%20multiple,exposure%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

<a id="ibrance-cyp3a-inhibitor-dose"></a>

### What Ibrance dose is used with a strong CYP3A inhibitor?

> “Avoid concomitant use of strong CYP3A inhibitors and consider an alternative concomitant medication with no or minimal CYP3A inhibition. If patients must be coadministered a strong CYP3A inhibitor, reduce the IBRANCE dose to 75 mg once daily. If the strong inhibitor is discontinued, increase the IBRANCE dose (after 3 to 5 half-lives of the inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Avoid%20concomitant%20use%20of%20strong,%287.1%29%20and%20Clinical%20Pharmacology%20%2812.3%29%5D.)

<a id="ibrance-grapefruit"></a>

### Can you eat grapefruit while taking Ibrance?

> “Grapefruit may interact with IBRANCE. Patients should not consume grapefruit products while on treatment with IBRANCE.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Grapefruit%20may%20interact%20with%20IBRANCE.,while%20on%20treatment%20with%20IBRANCE.)

> “Avoid grapefruit and grapefruit products during treatment with IBRANCE. Grapefruit may increase the amount of IBRANCE in your blood.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Avoid%20grapefruit%20and%20grapefruit%20products,of%20IBRANCE%20in%20your%20blood.)

<a id="ibrance-ppis-antacids"></a>

### Can Ibrance tablets or capsules be taken with PPIs or antacids?

> “IBRANCE tablets can be taken with or without food and can be coadministered with PPIs or antacids, whereas capsules must be taken with food.”

Source: [IBRANCE: Tablets & Capsules, captured 2026-11-13](https://ibrance.pfizerpro.com/dosing/tablets-capsules#:~:text=IBRANCE%20tablets%20can%20be%20taken,must%20be%20taken%20with%20food.)

> “Gastric pH Elevating Medications: In a drug interaction trial in healthy subjects, coadministration of a single 125 mg IBRANCE tablet with multiple doses of the proton pump inhibitor (PPI) rabeprazole under overnight fasted conditions had no effect on the rate and extent of absorption of palbociclib when compared to a single 125 mg IBRANCE tablet administered alone. Given the reduced effect on gastric pH of H2-receptor antagonists and local antacids compared to PPIs, an effect of these classes of acid reducing agents on palbociclib exposure is not expected.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Gastric%20pH%20Elevating%20Medications%3A%20In,palbociclib%20exposure%20is%20not%20expected.)

> “Gastric pH Elevating Medications: In a drug interaction trial in healthy subjects, coadministration of a single 125 mg dose of IBRANCE with multiple doses of the proton pump inhibitor (PPI) rabeprazole under fed conditions decreased palbociclib Cmax by 41%, but had limited impact on AUCINF (13% decrease), when compared to a single dose of IBRANCE administered alone. Given the reduced effect on gastric pH of H2-receptor antagonists and local antacids compared to PPIs, the effect of these classes of acid-reducing agents on palbociclib exposure under fed conditions is expected to be minimal. Under fed conditions there is no clinically relevant effect of PPIs, H2-receptor antagonists, or local antacids on palbociclib exposure. In another healthy subject study, coadministration of a single dose of IBRANCE with multiple doses of the PPI rabeprazole under fasted conditions decreased palbociclib AUCINF and Cmax by 62% and 80%, respectively, when compared to a single dose of IBRANCE administered alone.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191#:~:text=Gastric%20pH%20Elevating%20Medications%3A%20In,when%20compared%20to%20a%20single%20dose%20of%20IBRANCE%20administered%20alone.)

Note: The second passage is from the IBRANCE tablets Prescribing Information and the third, on fed and fasted conditions, from the IBRANCE capsules Prescribing Information.

## Related pages
- [Medical information: Ibrance (palbociclib): All indications](https://www.evicenter.com/medical-information/ibrance)
- [Indication](https://www.evicenter.com/medical-information/ibrance/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ibrance/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/ibrance/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ibrance/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/ibrance/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ibrance/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ibrance/access-and-coverage)
